Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-03 · accession 0001867096-25-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-07 | 2025-01-03 | XERS | JOHNSON KENNETH ERLAND | See Remarks | F - Tax | $3.61 | -12.4K | 361.8K | -3% | -$44.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-03 | F | D | 12,401 | $3.61 | 361,764 | D | — | — | (F1) Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested as of January 3, 2025. (F2) Includes 1,129 shares acquired on December 31, 2024 under the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, as amended. |